Helicobacter Pylori Eradication in Patients with Chronic Renal Failure

Gastrointestinal (GI) complains are common in hemodialysis patients. More than 80% of patients undergoing regular dialysis have similar complaints, such as dyspepsia. Moreover, the rate of GI bleeding is high in patients with chronic renal failure comparing with normal population. Peptic ulcer disease in non-dialysis patients is associated with two main factors: a) Helicobacter Pylori (H.P) infection and b) use of Non Steroidal Anti Inflammatory Drugs (NSAIDs(. The incidence rate of H.P infection in patient undergoing regular dialysis is controversial. The aim of this study was to evaluate the response to the H.P eradication therapy among patients undergoing dialysis. In this analytical study, 100 people with chronic dyspepsia with normal renal function and 80 dialyzed patients who were kidney transplant candidates with the inclusion criteria underwent upper GI endoscopy. H.P infections in those who had a positive rapid urease test or positive histology for Helicobacter and nominated for H.P treatment were enrolled. These patients received triple therapy against H.P for 2 weeks followed by 2 weeks received PPI and 4 weeks after cessation of treatment, Eradication was assessed by urease breath test (UBT). The successful eradication was found in 87% and 84% of the dialysis and control groups, respectively. Both dialysis group and the control group, who received furazolidone, had 100% eradication. In dialysis patients. From 54 patients who received clarithromycin, 81.5% have been successful in. H.P eradication. In the control group, 67 patients who received clarithromycin 76.1% have been successful in. H.P eradication. Eradication of H.P in dialysis and control groups showed no significant differences. Meanwhile the frequency of eradication with furazolidone was significantly more than clarithromycin.